Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2023 08:42 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J.,...
May 31, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study

Time to maximum blood concentration (median Tmax) for Anaphylm was 10 minutes with a range of 5 to 20 minutesEarly drug exposure at 10 minutes (partial area under the curve, or pAUC0-10min) for...
May 02, 2023 16:31 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Continues to advance development of AQST-109 (epinephrine sublingual film); received FDA conditional approval of brand name Anaphylm™Raises full year 2023 revenue and non-GAAP adjusted EBITDA...
April 26, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
April 20, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)

WARREN, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
April 18, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET

WARREN, N.J., April 18, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...
March 29, 2023 08:30 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets

WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
March 07, 2023 16:01 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

Pivotal study for AQST-109 (epinephrine sublingual film) on track to start in third quarter 2023Financial turnaround actions on track including 18% reduction of outstanding debt and the receipt of $20...
March 01, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

WARREN, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
February 22, 2023 08:00 ET | Source: Aquestive Therapeutics, Inc.

Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET

WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients’ problems...